

Amendment No. 1 to SB2532

Bell
Signature of Sponsor

AMEND Senate Bill No. 2532

House Bill No. 2641*

by deleting all language after the enacting clause and substituting instead the following:

SECTION 1. Tennessee Code Annotated, Section 68-7-101(5), is amended by adding the following as new subdivisions:

- () Trigeminal neuralgia;
- () Quadriplegia or paraplegia;
- () A patient's disease or condition that qualifies the patient to participate in a clinical research program involving medical cannabis; provided, that the disease or condition is deemed qualifying only during the course of the clinical research program and during the patient's participation in the program;

SECTION 2. Tennessee Code Annotated, Section 68-7-101, is amended by adding the following as a new subdivision:

() "Clinical research program" means a medical or clinical research trial or study involving the medical use of cannabis that:

- (A) Has been approved by the federal food and drug administration;
- (B) Is being conducted by or with funds provided from the national institute on drug abuse (NIDA); or
- (C) Is being conducted by a university, medical school, pharmacy school, or hospital;

SECTION 3. Tennessee Code Annotated, Section 68-7-109(a), is amended by adding the following as new subdivisions:

- () Hemp-derived cannabinoids, including, but not limited to:

- (A) Delta-8 tetrahydrocannabinol;
- (B) Delta-10 tetrahydrocannabinol; and
- (C) Hexahydrocannabinol;

() Increasing patient access and participation in clinical research programs in this state and throughout the country and ensuring the ability of participants to possess cannabis-based medicines in this state that are used as part of the clinical research programs;

() Authorizing the medical use of cannabis for chronic pain and intractable pain, and establishing safeguards related to the qualifying of such conditions;

() Creating a fiscally sound and financially viable program, including patient registration, at minimal state expense;

SECTION 4. Tennessee Code Annotated, Section 39-17-402(16)(F)(ii)(b)(2), is amended by adding the following as new subdivisions:

() Trigeminal neuralgia;

() Quadriplegia or paraplegia;

() A disease or condition that qualifies the person to participate in a clinical research program involving medical cannabis; provided, that the disease or condition is deemed qualifying only during the course of the clinical research program and during the person's participation in the program as a patient;

SECTION 5. This act takes effect upon becoming a law, the public welfare requiring it.